Serenoa Repens Monotherapy For Benign Prostatic Hyperplasia (BPH): An Updated Cochrane Systematic Review
Notes for this study:
||Weighted mean difference versus placebo was insignificant (-0.16 for IPSS/AUASI scores, 0.40 mL/s for maximum urinary flow rates) for medium- and long-term trials
|Number of Subjects
17 randomized trials of saw palmetto monotherapy in mostly white men with BPH were examined with study lengths ranging from 4-72 weeks. Saw palmetto was found to be no better than placebo for reducing lower urinary tract symptoms or maximum urinary flow rate. A long-term study found no effect on nighttime urination frequency, but pooling shorter-term studies found a reduction in frequency of 0.79 times per night on average, although the studies were heterogeneous. Adverse events were not statistically different from placebo.
Funding issues for this study: